CRNX vs TENX
CRNX: Crinetics Pharmaceuticals is a clinical-stage biotechnology company developing small molecule precision medicines for rare endocrine diseases and related tumors. TENX: Tenax Therapeutics is a clinical-stage biotechnology company developing specialized therapies for pulmonary hypertension and other cardiopulmonary conditions.
Side-by-side fundamentals
| Metric | CRNX | TENX | Edge |
|---|---|---|---|
| Price as of 2026-08-04 close | $83.86 | $16.19 | |
| Market cap as of 2026-08-05 | $8.8B | $429M | |
| PEG as of 2026-08-05 | -0.73 | -0.16 | CRNX lower |
| Net margin as of 2026-08-05 | -2747.2% | -10115.8% | CRNX higher |
| Gross margin as of 2026-08-05 | +86.0% | +100.0% | TENX higher |
| Operating margin as of 2026-08-05 | -3020.3% | -10390.5% | CRNX higher |
| ROE as of 2026-08-05 | -44.0% | -56.3% | CRNX higher |
| ROA as of 2026-08-05 | -39.6% | -53.1% | CRNX higher |
| Debt / equity as of 2026-08-05 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-08-05 | +2277.5% | -82.9% | CRNX higher |
| Beta as of 2026-08-05 | 0.02 | 1.07 | |
| 1-year return as of 2026-08-04 close | +197.2% | +167.6% | CRNX higher |
Fundamentals: market data, as of 2026-08-05. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-04.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.